Kinnate Biopharma Future Growth

Future criteria checks 0/6

Kinnate Biopharma is forecast to grow earnings and revenue by 17% and 59.7% per annum respectively while EPS is expected to grow by 33.9% per annum.

Key information

17.0%

Earnings growth rate

33.9%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	59.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	16 Feb 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

MUN:6KB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-74	-40	-31	3
12/31/2025	N/A	-58	-42	-43	4
12/31/2024	N/A	-66	-55	-74	6
12/31/2023	N/A	-118	-96	-95	6
9/30/2023	N/A	-127	-107	-106	N/A
6/30/2023	N/A	-127	-102	-102	N/A
3/31/2023	N/A	-122	-96	-96	N/A
12/31/2022	N/A	-116	-92	-89	N/A
9/30/2022	N/A	-111	-91	-88	N/A
6/30/2022	N/A	-105	-88	-85	N/A
3/31/2022	N/A	-99	-81	-79	N/A
12/31/2021	N/A	-90	-72	-71	N/A
9/30/2021	N/A	-77	-62	-62	N/A
6/30/2021	N/A	-63	-53	-53	N/A
3/31/2021	N/A	-49	-41	-41	N/A
12/31/2020	N/A	-36	-30	-30	N/A
9/30/2020	N/A	-26	-20	-20	N/A
12/31/2019	N/A	-10	-11	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6KB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6KB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6KB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6KB is forecast to have no revenue next year.

High Growth Revenue: 6KB is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 6KB's Return on Equity is forecast to be high in 3 years time

Kinnate Biopharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Kinnate Biopharma Files Form 15

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

XOMA Corporation (NasdaqGM:XOMA) entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. (NasdaqGS:KNTE) for approximately $120 million.

Kinnate Biopharma Inc. Announces Workforce Restructuring

New minor risk - Market cap size

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Kinnate Biopharma Inc. Appoints Jill DeSimone as Independent Director, Effective on March 1, 2023

Kinnate Biopharma Inc. to Present Trials in Progress Poster for Its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium

High number of new and inexperienced directors

Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor

Kinnate Biopharma Inc. Announces Pipeline Update

Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from Russell 2000 Growth Index

Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022

High number of new and inexperienced directors

Kinnate Biopharma Inc., Annual General Meeting, Jun 10, 2022

Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Its FGFR Inhibitor Product Candidate, KIN-3248

Kinnate Biopharma Inc. Highlights Data from its Lead RAF Candidate, KIN-2787, and RAF Clinico-Genomics Landscape Studies at the American Association for Cancer Research Annual Meeting

Chief Medical Officer recently bought €308k worth of stock

Kinnate Biopharma Inc. Announces Acceptance of Abstracts for Presentation At the American Association for Cancer Research Annual Meeting

Kinnate Biopharma Inc. to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer Meeting

Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers Symposium

Kinnate Biopharma Inc. Announces U.S Food and Drug Administration Clearance of Investigational Drug Application for KIN-3248

Kinnate Biopharma Inc. Announces That the First Patient Has Commenced Treatment in its Phase 1 KN-8701 Clinical Trial

Director Stephen Kaldor has left the company

Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021

Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF Kinase Inhibitor Program at Annual ASCO Meeting

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies